Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Continued progress in advancing varoglutamstat in kidney disease based on encouraging data and expansion of IP ...

The firm will assess irpagratinib plus best supportive care in patients with FGF19-overexpressing advanced liver cancer.

Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment ...

Treatments for multiple myeloma, melanoma, NSCLC, phenylketonuria, C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are under review.

Originally designed as glucose-lowering medications, SGLT2 inhibitors provide benefits across the cardio-renal-metabolic ...

SGLT2 inhibitors have been shown to reduce risk of acute kidney injury, but whether kidney effects are modified by risk of acute dips in eGFR is unknown.

Dr Amit Rauthan, Head, Department and Consultant, Medical Oncology and Hemato-Oncology, Manipal Hospital, explains how the advancements in oncology are offering hope by transforming cancer into a more ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

Cancer patients found to have specific gene mutations or other biomarkers are being matched to precision treatments not ...

Enlicitide decanoate demonstrated meaningful LDL lowering in patients with heterozygous familial hypercholesterolemia and ...

Initially used for blood glucose control, the medications reduce cardiovascular events and mitigate heart failure ...